2-氨基-1,2-二(4-甲氧基苯基)乙醇 | 530-34-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 2-氨基-1,2-二(4-甲氧基苯基)乙醇
• 英文名称: 2-amino-1,2-dianisylethanol
• 英文别名: α'-amino-4,4'-dimethoxy-bibenzyl-α-ol；(4-Methoxy-phenyl)-(α-amino-4-methoxy-benzyl)-carbinol；Evaclin; Evadol; Isodianidylethanolamine; LC 2；2-amino-1,2-bis(4-methoxyphenyl)ethanol
• CAS: 530-34-7
• 化学式: C₁₆H₁₉NO₃
• 分子量: 273.332
• InChiKey: DUEBHXGFCXXGHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  64.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氨基-1,2-二(4-甲氧基苯基)乙醇 在 L-焦谷氨酸 作用下， 以 水 为溶剂， 生成 (-)-erythro-2-amino-1,2-dianisylethanol
  参考文献：
  名称：

  Optical Resolution of Fragrant Lactones

  摘要：

  Optical resolution of six chiral fragrant lactones (delta-jasmine lactone, massoia lactone, tuberolactone, pentynyllactone, delta-decalactone, and gamma-nonalactone) was investigated by means of either the diastereomeric salt formation method or the diastereomeric amide formation method. Using these procedures, we obtained each enantiomer from five of the six lactones, except for massoia lactone. All five lactones were obtained in a good yield and with high optical purity. Sensoric characteristics on both enantiomers and racemic modification of four lactones are given.

  DOI：

  10.3987/com-99-s149
• 作为产物：
  描述：

  meso-1,2-bis(4-methoxyphenyl)ethylenediamine 在 硫酸 、 水 、 sodium nitrite 作用下， 生成 2-氨基-1,2-二(4-甲氧基苯基)乙醇
  参考文献：
  名称：

  Fischer; Prause, Journal fur praktische Chemie (Leipzig 1954), 1908, vol. <2> 77, p. 128

  摘要：

  DOI：

文献信息

• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
  申请人：Cerulean Pharma Inc.

  公开号：US20130196906A1

  公开（公告）日：2013-08-01

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  提供了关于使用CDP-治疗剂偶联物治疗疾病或紊乱的方法，例如自身免疫疾病、炎症性疾病、中枢神经系统紊乱、心血管疾病或代谢紊乱。还提供了CDP-治疗剂偶联物、包含CDP-治疗剂偶联物的颗粒以及包含CDP-治疗剂偶联物的组合物。
• COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE
  申请人：CERULEAN PHARMA INC.

  公开号：US20180193486A1

  公开（公告）日：2018-07-12

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  提供了关于使用CDP-治疗剂偶联物治疗自身免疫疾病、炎症性疾病或癌症的方法。还提供了CDP-治疗剂偶联物、包含CDP-治疗剂偶联物的颗粒以及包含CDP-治疗剂偶联物的组合物。
• Treatment of genitourinary tract disorders
  申请人：——

  公开号：US20030170286A1

  公开（公告）日：2003-09-11

  Genitourinary system disorders are treated with therapeutic agents, and optionally further with radiation treatments.

  生殖泌尿系统疾病可以用治疗性药物进行治疗，必要时还可以进一步进行放射治疗。
• Prodrugs containing novel bio-cleavable linkers
  申请人：Satyam Apparao

  公开号：US20060046967A1

  公开（公告）日：2006-03-02

  The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.

  本发明提供了公式(I)的化合物或其药用可接受的盐。本发明还提供了包含一个或多个公式I的化合物或其中间体以及一个或多个药用可接受的载体、车辆或稀释剂的药物组合物。本发明进一步提供了包括制备方法和使用方法在内的前药，包括释放一氧化氮的前药、双前药和相互前药，由公式I的化合物组成。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。